Q&A: Mental health conditions underrecognized in patients with AMD
Healio spoke with Aleksandra Rachitskaya, MD, a vitreoretinal surgeon and associate professor of ophthalmology at Cleveland Clinic Cole Eye Institute, about mental health conditions in patients with age-related macular degeneration.
Good outcomes seen 9 months after switching to faricimab for wet AMD treatment
Eyes with neovascular age-related macular degeneration that switched to faricimab generally had lower rates of lesion activity, longer treatment intervals and stable visual acuity.
Q&A: Understanding the impact of socioeconomic disparities in AMD
Healio spoke with Bradley Dougherty, OD, PhD, associate professor at The Ohio State University College of Optometry, about how socioeconomic factors can affect the diagnosis, treatment and outcomes of age-related macular degeneration.
VIDEO: Port delivery system shows real-world efficacy, safety in neovascular AMD
PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, Arshad M. Khanani, MD, MA, FASRS, discusses efficacy and safety data for the port delivery system ahead of its reintroduction.
Low-dose aspirin use ‘should not be recommended’ to prevent, treat AMD
In an analysis of more than 3,100 older adults, low-dose aspirin administered for 3 years did not affect the incidence or progression of age-related macular degeneration, according to study results published in JAMA Ophthalmology.
Experts weigh current, future options for AMD management
The past 2 years have brought a decisive leap forward in the management of age-related macular degeneration.
VIDEO: AccuraSee intraocular pseudophakic contact lens investigated in AMD
BOSTON — In this Healio Video Perspective from Eyecelerator@ASCRS, Kevin J. Cady of OnPoint Vision provides an update on the AccuraSee intraocular pseudophakic contact lens.
Q&A: Stem cell patch aims to improve AMD vision loss
There are no current therapies to improve vision in patients with advanced age-related macular degeneration, but research on the safety of a stem cell patch has indicated positive results in patients suffering from vision loss, according to researchers.
VIDEO: Sozinibercept in ‘last push’ of phase 3 clinical development
SAN FRANCISCO — In this Healio Video Perspective from Eyecelerator@AAO, Megan Baldwin, PhD, of Opthea, shares an update on sozinibercept, a VEGF-C/D inhibitor for the treatment of neovascular age-related macular degeneration.
Retinal stimulation microchip shows encouraging outcomes in severe atrophic AMD
The first-in-human trial assessing the safety and efficacy of the PRIMA photovoltaic retinal stimulation microchip for severe central vision impairment due to dry age-related macular degeneration showed positive outcomes at 4 years.